Dividend Stock Portfolio for Retirement: Pfizer’s (PFE) Reliable Payouts

Core Viewpoint - Pfizer Inc. is recognized as a strong candidate for a dividend stock portfolio, despite facing challenges in the past three years due to fluctuating demand for its COVID-19 vaccine and treatment, resulting in a nearly 50% decline in stock price [2][4]. Group 1: Company Overview - Pfizer Inc. is an American multinational pharmaceutical and biotech company [2]. - The company has experienced significant stock price volatility, particularly related to its COVID-19 products [2]. Group 2: Future Growth Potential - Pfizer's pipeline includes promising candidates such as Elrexfio and Sigvotatug vedotin, which could drive future revenue growth [3]. - Elrexfio is approved for certain multiple myeloma patients, with ongoing phase 3 trials that may broaden its application [3]. - Sigvotatug vedotin, acquired through the purchase of Seagen, has shown strong results in phase 3 trials for advanced lung cancer [3]. Group 3: Financial Performance and Dividends - Pfizer currently has 18 oncology drugs in phase 3 development, with eight expected to potentially generate over $1 billion in annual sales each by 2030 [4]. - The company has consistently grown its dividends for 15 consecutive years, currently paying a quarterly dividend of $0.43 per share [4]. - As of September 21, Pfizer's stock has a dividend yield of 7.16% [4].